BridgeMD
New treatment option for Inflammatory Bowel Disease (IBD)
Official title Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)
ClinicalTrials.gov ID: NCT07191106
What this study is testing
- What it's testing
- Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18 years and older
- Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months
- Patient is motivated to participate in the Adapted Physical Activity (APA) program
- Medical certificate confirming fitness to engage in remote physical activity
- Access to a digital device with internet connectivity enabling use of the MOOV+ application at home
You likely can't join if
- Patients under 18 years of age
- Medical contraindication to physical activity
- High levels of physical activity as defined by the International Physical Activity Questionnaire (IPAQ):
- Total \>1500 MET-min/week of vigorous activity on at least 3 days, OR
- Total physical activity \>3000 MET-min/week, regardless of distribution
- Presence of psychological disorders that may interfere with study participation
See the full eligibility criteria
- Adults aged 18 years and older
- Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months
- Patient is motivated to participate in the Adapted Physical Activity (APA) program
- Medical certificate confirming fitness to engage in remote physical activity
- Access to a digital device with internet connectivity enabling use of the MOOV+ application at home
- Written informed consent freely given after appropriate information
- Affiliation with, or beneficiary of, a national health insurance system
- Patients under 18 years of age
- Medical contraindication to physical activity
- High levels of physical activity as defined by the International Physical Activity Questionnaire (IPAQ):
- Total \>1500 MET-min/week of vigorous activity on at least 3 days, OR
- Total physical activity \>3000 MET-min/week, regardless of distribution
- Presence of psychological disorders that may interfere with study participation
- Lack of access to a device or internet connection enabling remote participation
- Pregnant or breastfeeding women
- Patients under legal guardianship or curatorship
- Patients under legal protection
The study team makes the final eligibility decision.
Where it's taking place
- Montfermeil, France
- Nantes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montfermeil, France; Nantes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.